Literature DB >> 2706188

Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

L Borgström1, L Nyberg, S Jönsson, C Lindberg, J Paulson.   

Abstract

1. The pharmacokinetics of the two enantiomers of terbutaline, (+)T and (-)T, and the racemate (+/-)T, have been evaluated after single intravenous and oral dosage to six healthy volunteers. 2. The mean systemic clearance, CL, was 0.19 and 0.13 l h-1 kg-1 for (+)T and (-)T, respectively. This difference was statistically significant. The mean clearance of (+/-)T was 0.20 l h-1 kg-1. Volumes of distribution were similar (1.9 l kg-1) after the three intravenous administrations. The differences in CL were reflected in values of the elimination half-life and MRT. 3. The difference in CL of the isomers could be explained by a corresponding difference in their renal clearance, CLR. Competition for stereoselective active reabsorption in the tubule might explain why (+)T seemed to enhance the CLR of (-)T when the drug was given as the racemate. 4. Oral bioavailability, calculated from plasma data, of (+)T was 7.5% and that of (-)T was 14.8%. This difference was statistically significant and was mainly due to a difference in absorption of (+)T and (-)T, but also to a difference in their subsequent first-pass metabolism. The bioavailability of (+/-)T was similar to that of (-)T. 5. (-)T appears to govern the absorption properties of the racemate, while (+)T determines its elimination behaviour. Systemic metabolism of the two enantiomers was similar and, therefore, a greater first-pass metabolism of (+)T would reflect a higher capacity of the gut wall to metabolise this isomer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706188      PMCID: PMC1379704          DOI: 10.1111/j.1365-2125.1989.tb05334.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Effects of structural modifications of catecholamines on renal tubular transport in the chicken.

Authors:  A J Quebbemann; B R Rennick
Journal:  J Pharmacol Exp Ther       Date:  1969-03       Impact factor: 4.030

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Enhancement effect of methylxanthines on the intestinal absorption of poorly absorbable dyes from the rat small intestine.

Authors:  J Nakamura; R Takamura; T Kimura; S Muranishi; H Sezaki
Journal:  Biochem Pharmacol       Date:  1979-10-01       Impact factor: 5.858

Review 4.  Renal tubule transport of organic cations.

Authors:  B R Rennick
Journal:  Am J Physiol       Date:  1981-02

5.  Resolution of terbutaline, a new -sympathomimetic amine.

Authors:  K Wetterlin
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

6.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

7.  Stereoselective renal tubular secretion of quinidine and quinine.

Authors:  D A Notterman; D E Drayer; L Metakis; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1986-11       Impact factor: 6.875

8.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Authors:  B Vogelgesang; H Echizen; E Schmidt; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Determination of terbutaline in plasma by gas chromatography chemical ionization mass spectrometry.

Authors:  S E Jacobsson; S Jönsson; C Lindberg; L A Svensson
Journal:  Biomed Mass Spectrom       Date:  1980-06

10.  Pharmacokinetics of (+/-)-, (+)-, and (-)-gossypol in humans and dogs.

Authors:  D F Wu; Y W Yu; Z M Tang; M Z Wang
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

View more
  33 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

2.  Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers.

Authors:  B Schmekel; L Borgström; P Wollmer
Journal:  Thorax       Date:  1991-04       Impact factor: 9.139

3.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

4.  Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation.

Authors:  Selma Sahin; Yasemin Karabey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

5.  Pharmacokinetics of terbutaline in chronic kidney disease.

Authors:  Anders Bastiansen; Sarah Eggert; Erland Pedersen
Journal:  Eur J Clin Pharmacol       Date:  2013-07-31       Impact factor: 2.953

6.  Insights into the permeability of drugs and drug-like molecules from MI-QSAR and HQSAR studies.

Authors:  Ranajit N Shinde; K Srikanth; M Elizabeth Sobhia
Journal:  J Mol Model       Date:  2011-06-03       Impact factor: 1.810

Review 7.  Chirality. Clinical pharmacokinetic and pharmacodynamic considerations.

Authors:  E J Lee; K M Williams
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

8.  Stereoselective metabolism of RS-albuterol in humans.

Authors:  T Walle; E A Eaton; U K Walle; G R Pesola
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

9.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

10.  Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.

Authors:  U K Walle; G R Pesola; T Walle
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.